Form 4: Xilio Therapeutics Director Boosts Stake with Open Market Share Purchases
Insider Transaction Report
A director at Xilio Therapeutics, Inc. has reported the acquisition of 70,000 shares of common stock through open market purchases in mid-June 2025, signaling increased insider confidence.
Summary
- James Samuel Shannon, a Director of Xilio Therapeutics, Inc. (XLO), acquired a total of 70,000 shares of common stock through open market purchases.
- On June 16, 2025, Mr. Shannon purchased 45,000 shares at a weighted average price of $0.686 per share, with prices ranging from $0.6799 to $0.6891.
- On June 17, 2025, an additional 25,000 shares were purchased at a weighted average price of $0.6886 per share, with prices ranging from $0.6659 to $0.6991.
- Following these transactions, Mr. Shannon directly beneficially owns 70,000 shares of Xilio Therapeutics common stock.
- The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
Sentiment
Score: 7
Explanation: The sentiment is positive as a director's open market purchase of shares indicates confidence in the company's future performance and valuation, aligning insider interests with shareholders.
Positives
- A director's open market purchase of shares typically signals confidence in the company's future prospects and valuation.
- The acquisition of 70,000 shares represents a notable increase in the director's direct beneficial ownership, aligning insider interests with shareholders.
Future Outlook
This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
Insider buying, particularly by a director, can be viewed positively across industries, including biotechnology (implied for Xilio Therapeutics), as it suggests management's belief in the company's value and future prospects, potentially indicating an undervaluation or upcoming positive developments.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transactions were executed under a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged schedule for buying or selling shares to avoid accusations of trading on material non-public information. | N/A | Enhances transparency and provides a legal affirmative defense against insider trading allegations, reflecting adherence to corporate governance best practices for insider transactions. |
Stakeholder Impact
- Shareholders: May view the director's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
- Employees: Could interpret the insider buying as a sign of stability and positive future outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 06/16/2025 | Date of first common stock acquisition by Director James Samuel Shannon (45,000 shares). |
| 06/17/2025 | Date of second common stock acquisition by Director James Samuel Shannon (25,000 shares). |
| 06/18/2025 | Date the Form 4 filing was signed and submitted. |
Recommendation
holdKeywords
Xilio Therapeutics, XLO, Insider Trading, Form 4, Director Purchase, Common Stock, Equity Acquisition, James Samuel Shannon, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.